Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage

Modern Pathology

Volumn 26, Issue 12, 2013, Pages 1577-1585

  Boiocchi, Leonardo ^a,b,d   Mathew, Susan ^a   Gianelli, Umberto ^b   Iurlo, Alessandra ^c   Radice, Tommaso ^c   Barouk Fox, Sharon ^a   Knowles, Daniel M ^a   Orazi, Attilio ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Bone marrow biopsy; Cytogenetics; Myeloproliferative neoplasms; Post polycythemic myelofibrosis; Primary myelofibrosis

Indexed keywords

JANUS KINASE 2;

ADULT; ARTICLE; CELL MATURATION; CHROMATIN; CHROMOSOME 1; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; GENETIC DAMAGE; HUMAN; HUMAN CELL; KARYOTYPE; MALE; MEGAKARYOCYTE; MORPHOLOGY; MYELOFIBROSIS; MYELOID METAPLASIA; POLYCYTHEMIA VERA; POST POLYCYTHEMIC MYELOFIBROSIS; PRIORITY JOURNAL;

ABNORMAL KARYOTYPE; AGED; CYTOGENETIC ANALYSIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JANUS KINASE 2; KAPLAN-MEIER ESTIMATE; MALE; MEGAKARYOCYTES; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIMARY MYELOFIBROSIS;

EID: 84889078595     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.109     Document Type: Article

References (19)

1. Thiele J, Kvasnicka HM, Orazi A, et al. Polycythaemia vera. In: Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008, pp 40-43.
2. Thiele J, Kvasnicka HM, Tefferi A, et al. Primary myelofibrosis. In: Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008, pp 44-47.
3. Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol 2012;158:453-471.
4. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132. (Pubitemid 41323513)
5. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: New York, NY, USA, 1989.
6. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365: 1054-1061. (Pubitemid 40386783)
7. Shaffer LG, Slovak ML, Campbell LJ (eds) ISCN (2009): An International system for Human Cytogenetic Nomenclature. Karger: Basel, 2009.
8. Helbig G, Wieczorkiewicz A, Wozniczka K, et al. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis. Med Oncol 2012;29: 2379-2384.
9. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-1579.
10. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol 2009;82:329-338.
11. Santana-Davila R, Tefferi A, Holtan SG, et al. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and-negative cases. Leuk Res 2008;32:1927-1930.
12. Andrieux JL, Demory JL. Karyotype and molecular cytogenetic studies in polycythemia vera. Curr Hematol Rep 2005;4:224-229.
13. Westwood NB, Gruszka-Westwood AM, Pearson CE, et al. The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization. Br J Haematol 2000;110: 839-846.
14. Andrieux J, Demory JL, Caulier MT, et al. Karyotypic abnormalities in myelofibrosis following polycythemia vera. Cancer Genet Cytogenet 2003;140:118-123. (Pubitemid 36349011)
15. Rumi E, Harutyunyan A, Elena C, et al. Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. Am J Hematol 2011;86:974-979.
16. Cervantes F, Pereira A. Prognostication in primary myelofibrosis. Curr Hematol Malig Rep 2012;7:43-49.
17. Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in postpolycythemia vera myelofibrosis. Blood 2008;111: 3383-3387.
18. Barosi G. Emerging targeted therapies in myelofibrosis. Expert Rev Hematol 2012;5:313-324.
19. Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 2012;30:2981-2987.